Pharmacokinetics of clorazepate in pregnant and non-pregnant women
| Autor: | J. Chavinie, P. d'Athis, Elisabeth Rey, P. Giraux, Georges Olive, D. de Lauture, J. M. Turquais |
|---|---|
| Rok vydání: | 1979 |
| Předmět: |
Adult
medicine.medical_specialty Physiology Urine Pharmacokinetics Pregnancy medicine Humans Clorazepate Pharmacology (medical) Biotransformation Clorazepate Dipotassium reproductive and urinary physiology Pharmacology Gynecology Volume of distribution business.industry Half-life General Medicine medicine.disease Body Fluids Kinetics Anti-Anxiety Agents Female Biological half-life business Intramuscular injection Half-Life medicine.drug |
| Zdroj: | European Journal of Clinical Pharmacology. 15:175-180 |
| ISSN: | 1432-1041 0031-6970 |
| DOI: | 10.1007/bf00563102 |
| Popis: | A single dose of clorazepate 20 mg was injected i.m. in 7 pregnant and 7 non-pregnant women. Blood samples were collected for one week, and urine was collected for 24 h after the dose. The concentrations of clorazepate and its metabolite nordiazepam were determined by electron capture gas liquid chromatography. There was no difference between the two groups on physical examinations. Clorazepate was rapidly absorbed and the peak concentration was reached within 2 h. Mean pharmacokinetic parameters for clorazepate were absorption half life 0.77 h in pregnant women and 0.56 h in non-pregnant women; elimination half life 1.3 h in pregnant women and 2.0 h in non-pregnant women; volume of distribution: 0.43 1 . kg-1 in the pregnant women and 0.33 1 . kg-1 in non-pregnant women. Nordiazepam reached its peak concentration within 12 h after dosing; its mean half life of elimination was 180 h in pregnant women and 60 h in non-pregnant women. Within 24 h, 1.3% of the clorazepate was recovered in urine from pregnant women and 7% in urine from the non-pregnant women. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink